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thereby influencing the function of numerous 
enzymes and transcription factors that cont-
rol cell proliferation, apoptosis and signalling 
pathways [4,5]. Abnormal MT function and 
expression have been implicated in various 
human diseases, including cancer [6]. There 
are at least 10 isoforms of MT in human body, 
which are expressed in a tissue specific pattern 
and may play distinct roles in the various cell 
types. MT-I and MT-II isoforms are present in 
all cells throughout the body, MT-III was first 
isolated as a growth inhibiting factor (GIF) from 
brain neurons, MT-IV is located in stratified 
epithelium [6]. Transcription of MT-I and MT-
-II can be induced by inflammatory cytokines 
(IL-6, TNF-α, interferons), lipopolysaccharids, 
glucocorticoids, free radicals, antioxidants or 
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1. Introduction
Zinc (Zn (II)) is an essential microelement, it 
has critical role in normal health and develop-
ment [1]. Binding of Zn (II) to zinc coordination 
motifs in proteins stabilizes the structure or 
influences the function. The prevalence of genes 
encoding zinc proteins is estimated to be over 
3% of the 32,000 identified genes. Over 300 
Zn (II)-dependent enzymes have been defined 
and characterized [2]. It has been shown that 
Zn (II) can regulate the DNA-binding activity 
of zinc finger transcription factors [3]. The Zn 
(II)-metallothionein (MT)/thionein pair, which 
is an important component of cellular Zn (II) 
homeostasis, is critical to sequester or release 
Zn(II) depending on the local redox state, 
All human tissues consist of a wide variety of cells that have an impact on each other. 
Human diseases that are caused by genetic alterations and/or environmental factors can be 
characterized by morphological and functional changes in tissues. Both aspects are important 
to better understand the pathomechanism of a disease and to find new therapeutic targets. 
Immunohistochemistry identifies the expression, intracellular localization as well as tissue 
distribution of various proteins, while morphology of tissue can also be assessed precisely. 
It is used for routine diagnostics as well as for research. However, antigen specific assay 
standardization and the use of appropriate positive and negative tissue controls are very 
important to interpret the findings in a way that ensures the biological relevance. Abnormal 
metallothionein function and expression have been implicated in various human diseases, 
including cancer. Immunohistochemistry provides an excellent opportunity to gain an insight 
into the role of MT in the pathogenesis of diseases.
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heavy metals. MT is a cytosolic protein in res-
ting cells, but it can be translocated transiently 
to the cell nucleus during cell proliferation and 
differentiation [7].
Immunohistochemistry (IHC) identifies the 
expression, intracellular localization as well 
as tissue distribution of various proteins, whi-
le morphology of tissue can also be assessed 
precisely [8]. IHC detection of MT in tissue 
samples is a very important option to study its 
role in the pathogenesis of diseases. Special 
IHC methods such as multiple immunolabeling 
using serial sections of tissue blocks or double 
staining technique provide an opportunity to 
study correlations between MT expression and 
important cell and tissue functions [9]. Tissue 
microarray allows simultaneous examination of 
large number of tissues on a single microscope 
slide; therefore it is very suitable to evaluate the 
diagnostic, prognostic or predictive role of the 
MT expression [9].
2.Immunohistochemical  
detection of metallothionein
The IHC technique is a combination of immu-
nologic and chemical reactions visualized with 
a photonic microscope [8]. It can be divided in 
pre-analytical, analytical and post-analytical 
phases. It starts with tissue fixation, embed-
ding, and tissue sectioning, followed by depa-
raffinization, antigen retrieval, blocking of non-
specific activities, incubation with the primary 
antibody, and labeling of the antigen-antibody 
reaction, and ends with slide counterstaining, 
coverslipping and evaluation (Figure 1.). Most 
commonly, formalin-fixation and paraffin-em-
bedding (FFPE) is used for its ability to preserve 
tissue indefinitely for morphologic examination 
[8,10]. Heat-induced epitope retrieval was pro-
ved to restore the immunoreactivity of tissues 
fixed in formalin [8]
Figure 1: Outline of standard immunohistoche-
mical protocol [8,11,12].
2.1 Pre-analytical phase of 
immunohistochemistry
The aim of fixation is to maintain morphologi-
cal features and to preserve tissue suitable for a 
range of staining and IHC [11]. Adequate tissue 
fixation is very important to stabilize proteins 
and prevent tissue decay. Tissue fixation may 
be accomplished by physical (freeze) and/or 
chemical (coagulative and cross-linking) me-
thods. For IHC purposes, the fixative of choice 
is a 10% neutral-buffered formalin solution. 
The specimen should be placed in fixative im-
mediately after it is removed from the patient. 
The volume of formalin should be 10 to 20 times 
the volume of specimen. Delayed, too short or 
too long fixation can lead to false IHC results 
[8]. Formaldehyde penetrates the tissue very 
quickly, but fixes it very slowly; 16-24 h fixation 
time is required for a tissue specimen of 1-4 mm 
in diameter. Large specimens should be cut into 
slices 4 to 5 mm thick for further fixation [11].
Tissue processing refers to a series of steps that 
include removal of the extractable water and 
lipids from the tissue, usually in an automated 
manner, then infiltration and embedding in a 
support matrix (paraffin) so that the tissue can 
be stabilized and cut easily [11]. The specimens 
are cut on a rotary microtome into sections 3 to 
5 μm thick. Sections that will be used for IHC 
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should be mounted on glass slides specially 
coated or charged to ensure better adherence 
[11]. Long-term storage of tissue sections is not 
recommended, because photo-oxidation of sec-
tions results in loss of antigenicity [8]. Detection 
of certain antigens has the limitation of requi-
ring fresh tissue. In this case the specimen is 
obtained fresh and kept moist until it is oriented 
and embedded in optimal cutting temperature 
(OCT) compound, then the specimen is snap 
frozen [11]. The tissue is then sectioned at 6 μm. 
Occasionally, special tissue processing (e.g., 
decalcification, demelanization) is required 
prior to the immunostaining, but epitopes can 
be destroyed by an aggressive procedure [8]. 
The standard of protocol for tissue fixation and 
processing must be developed for each antigens 
and tissue type. It is worth to highlight that 
pre-analytical factors influence the success of 
a subsequent nucleic acid analysis as well [10].
2.2 Analytical phase of
 immunohistochemistry
Tissue sections mounted on coated or charged 
glass slides are deparaffinized and rehydrated 
before antigen retrieval (AR). Incomplete depa-
raffinization causes suboptimal or incomplete 
staining because of incomplete tissue penetrati-
on by the antibody [12]. Heat- and/or protease-
-induced AR is a procedure which reverses the 
structural changes induced by the fixation and 
tissue processing [8]. AR techniques are critical 
for antigen unmasking, optimal results require 
control of the pH and temperature of retrieval 
solutions and controlled enzymatic digestion 
[12]. The mechanism of heat to restore the im-
munoreactivity of formalin-fixed tissues is not 
completely clear, the dissociation of irrelevant 
proteins from target peptides, hydrolysis of me-
thylene cross-links, restoring the native electro-
static charges, mobilization of trace paraffin 
etc. can be involved [8]. Enzymatic treatment 
is optimal only for few antigens and can alter 
tissue morphology or destroy epitopes [8].
Antigen epitopes consist of 5-6 amino acid 
residues, and are classified as linear or confor-
mational [8]. Antigens may consist of multiple 
identical or distinct epitopes. Antigen-antibody 
binding involves hydrophobic, van der Waals, 
and electrostatic interactions. The best diluents 
buffer for primary antibody is 0.05 to 0.1 M Tris 
buffer (pH 6.0) [8]. Background reactivity due to 
ionic interactions can be reduced by increasing 
the NaCl concentration in the buffer, but it can 
reduce the antigen-antibody binding [8]. Deter-
gents (e.g., Tween 20) are also used to facilitate 
antigen-antibody binding by solubilizing mem-
brane proteins; they are usually incorporated 
into dilution/rinse buffers [8]. Antibody con-
centrates and pre-diluted preparations must be 
optimized for usage at the correct dilution [12]. 
The affinity of an antibody for an antigen affects 
the sensitivity and specificity of an immunolo-
gical reaction [8]. The overall binding intensity 
between antibodies and a multivalent antigen 
is described by avidity. Polyclonal antibodies 
usually have higher avidity, but lower specificity 
compared with monoclonal antibodies [8]. The 
high specificity, however, does not eliminate 
the possibility of cross-reactivity with other 
antigens, because the target epitopes can be 
part of multiple proteins and peptides.
The most frequent reason for the failure of IHC 
is the poor quality of the primary antibody used. 
However, nonspecific background staining, less 
than optimal specific staining, or no staining 
require a careful evaluation of all components 
involved in each step of the IHC technique [13].
2.2.1 Detection system
Primary (direct detection), secondary or terti-
ary (indirect detection) antibodies labelled with 
enzymes, metals or fluorescent compounds are 
used to visualize the antigen-antibody reaction 
[8,12]. The detection system must be compatible 
with the species tested. The most common label 
is the horseradish peroxidase, which produces 
a coloured precipitate at the site of the antigen-
-antibody reaction in the presence of its spe-
cific substrate and chromogens. Endogenous 
peroxidase activity has to be blocked before 
incubation with primary antibody. Chromogen 
entrapment, precipitation and contaminants 
may lead to false-positive interpretation of an 
IHC test [12]. Three-step techniques are more 
sensitive, e.g., the labelled streptavidin-biotin 
(LSAB) method, which is widely used. In this 
case, a biotinylated secondary antibody binds 
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to the primary antibody attached to the tissue 
antigen, and the biotinylated complex is detec-
ted by streptavidin that has been conjugated 
to the enzyme. Nevertheless, the endogenous 
biotin-associated background staining has led 
to increasing use of labelled polymer-based 
detection systems that are characterized by 
greater sensitivity, specificity, and suitable for 
manual and automated IHC platforms. Simul-
taneous or sequential multiple labelling using 
various detection systems can be used to lo-
calize different antigens in the same sections. 
Quantum dot labelling is a promising new tool 
for multispectral analysis [8].
Frozen sections can be more appropriate to 
examine the expression of certain proteins. 
In this case, immunofluorescence is used for 
detection of antigen-antibody reaction. Pri-
mary (or secondary) antibodies are linked to a 
fluorescent label such as fluorescein isothiocya-
nate to allow visualization using a fluorescence 
microscope [12]. Compared to frozen sections, 
paraffin-embedded tissues offer the advantage 
of better preservation of cellular details and 
permanency of the reaction [11].
2.3 Post-analytical phase of
 immunohistochemistry
Post-analytical phase of IHC includes assay 
standardization/validation, control perfor-
mance, and interpretation of IHC results [8,14]. 
IHC assay standardization is important to ob-
tain consistent and reproducible results within 
each laboratory and comparable results among 
laboratories [8]. Standardization is the process 
of optimizing the test method (reagents and 
protocols). Guidelines for antigen-, tissue- and 
species-specific standardization of IHC exami-
nations should be based on currently available 
published evidence and modern understanding 
of quality assurance principles as applied to 
IHC in general [15]. Furthermore, diagnos-
tic IHC laboratories must meet the ISO 15189 
standards or standards of operation as defined 
by the Clinical Laboratory Improvement Amen-
dments, respectively [16]. In non-accredited 
laboratories, IHC tests should be validated by 
documentation of internal and external qua-
lity assessments [17]. Use of quality controls 
is required for technical calibration and ana-
lytical validation [14]. Positive tissue control is 
defined as tissue that is known to contain the 
antigen of interest. Positive and negative tissue 
controls must be fixed and stained in the same 
way as the tested specimen [8]. Positive tissue 
control in the tested specimen is designated as 
internal positive tissue control, e.g., MT immu-
noreactivity in basal layer of normal epidermis 
(Figure 2.). Negative reagent controls are used 
to confirm the specificity of the test and to assess 
the degree of nonspecific background staining 
present by omitting the primary antibody [14]. 
Validation detects any cross-reactivity of the 
selected antibodies with unrelated antigens, 
and cross-reactivity among different tissues and 
among different species, examines the variables 
that affect the IHC reaction, such as fixation 
time and storage of unstained tissue sections, 
and may include comparison of results among 
different laboratories using similar techniques 
[8]. Whenever possible, validation compares the 
sensitivity of IHC detection to the gold standard 
method of detection for the Ag in question.
According to the Clinical and Laboratory Stan-
dards Institute suggestions, the IHC report 
should include the cellular location and tissue 
distribution of the tested antigen, semi-quanti-
tative evaluation of the immunoreactivity, along 
with an interpretation of the test results [8,13-
15]. The report should contain demographic 
information, the tissue that was tested, disease 
characteristics, and the antibody used. IHC 
scoring schemes are based on a subjective as-
sessment of the labelling intensity and percent 
positive cells by a pathologist. Recently, it has 
been demonstrated that software algorithms 
are able to properly indicate the disease-relevant 
regions in digitized tissue images and quantify 
the area and optical density of positive staining 
[18,19]. Advantages of an automated digital IHC 
image analysis are that it is unbiased, precise in 
ranges of staining that appear weak to the eye, 
and produces continuous data [18].
2.4 Antibodies for metallothionein 
immunodetection
In mammals, four tandemly clustered MT 
genes are known [20]. In humans, MT-I has 
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undergone duplication events that have resulted 
in 13 duplicate isoforms, five of which have been 
predicted to be no active forms [20]. All genes 
encode for conserved peptide chains that retain 
20 invariant metal-binding cysteines. A total 
of 9 and 11 cysteines are required to form pro-
tein domains that bind three and four divalent 
metal ions [21]. MT-I and MT-II are 61-residue 
proteins, MT-III holds an extra residue in the 
β-domain and a six-residue long insertion in the 
α-domain, whereas MT-IV shares an additional 
residue in the β-domain [20]. In humans, the 
transcription of MT-I and MT-II isoforms is 
induced by various stimuli [21]. The expression 
of MT-II, MT-IE and MT-IX can be detected in 
most types of tissue, whereas the expression of 
other MT-I isoforms seems to be restricted to 
some tissues [20]. MT-III is constitutive tissue-
-specific isoform, it is expressed in human brain 
and in some other tissues [20]. MT-IV mRNA 
expression has been reported in stratified squa-
mous epithelium in mouse, no data exist on the 
expression of MT-IV in humans [20].
In order to investigate protein expression, the 
most widely used primary antibody to detect 
MT-I/II proteins in FFPE tissues of a number 
of different species is a monoclonal mouse an-
tibody (Clone E9, Dako) reacting with a single 
and highly conserved epitope formed by the last 
5-7 residues of the N-terminus of the β-domain 
of MT-I and MT-II [22-25]. The immunogen was 
horse self-polymerized MT-I and MT-II. In pre-
vious studies a specific polyclonal antibody that 
was generated against rat liver MT in rabbits 
was used efficiently to detect MT expression 
also in humans [7,26,27]. Furthermore, due 
to the difference in the amino acid sequence, 
specific monoclonal and polyclonal antibodies 
against MT-III could be generated and used 
successfully in IHC tests [22,28-30]. Further 
progress in the development of primary antibo-
dies against MT isoforms would be important 
for future investigations. Nevertheless, IHC 
studies to date have greatly contributed to the 
current knowledge on the functions of MT in 
the human body.
2.5 Tissue specific expression of 
metallothionein proteins
MT-I and MT-II can be expressed in all cells 
throughout the body, however, IHC examinati-
ons were able to reveal that not all cells express 
MT to the same extent in healthy tissues [27]. 
In addition, several factors, e.g., proliferation 
status, age, can influence the expression of MT. 
For example, in normal human skin, strong 
MT-I/II immunostaining can be detected in ba-
sal keratinocytes of epidermis and hair follicle 
outer root sheath, hair matrix cells and the 
secretory coil, but not in the exocrine portion 
of eccrine glands [31]. In hyperplastic epider-
mis the increased MT expression represents 
an increase in the germinative pool size [32]. 
Accordingly, the protein levels of MT-I and MT-II 
have been shown to decrease significantly with 
increasing age simultaneously with the decrease 
of keratinocyte proliferation [33]. Nartey et 
al. investigated the distribution of MT during 
human development [34]. They found that MT 
levels are higher in the fetal liver than in the 
adult liver; in addition, MT is localized in the 
nucleus and the cytoplasm of human fetal and 
neonatal hepatocytes, whereas MT is mainly 
expressed in the cytoplasm of adult liver cells. 
In the fetal and neonatal human kidney, MT 
is localized primarily in the nucleus and the 
cytoplasm of the proximal tubular epithelial 
cells, whereas in the adult kidney, intraluminal 
MT localization was also observed [34].
MT-III expression has been investigated by 
IHC in rats [28]. Some astrocytes in the deep 
layers of cortex, ependymal cells, some glo-
merular and tubular cells in the kidney, some 
glandular epithelial cells in the dorsolateral lobe 
of prostate, some Sertoli cells and Leydig cells 
in the testis, and taste bud cells in the tongue 
showed MT-III immunostaining [28].
2.5.1  Metallothionein expression 
in response to exogenous agents
It is thought that MTs exert cytoprotective 
effects against heavy metal toxicity and oxi-
dative stress [27]. IHC is suitable method to 
investigate the expression of MT in various 
tissues in response to an exogenous agent. An 
example is the elevated nuclear and cytoplasmic 
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MT expression of periportal hepatocytes, proxi-
mal tubular epithelial cells, intestinal columnar 
epithelial cells and Paneth cells in rats during 
dietary copper or zinc overloads, and upon 
exposure to cadmium [25,35,36]. Furthermore, 
the hepatic MT levels were increased in both 
the nucleus and cytoplasm of hepatocytes in 
mice upon thioacetamide exposure [37], and 
in rats upon exposure to 2,3,7,8-tetrachlorodi-
benzo-p-dioxin [38]. Increased MT-I and MT-II 
expression in the renal proximal tubular cells of 
rats upon administration of doxorubicin might 
indicate a protective mechanism against the 
pro-apoptotic effect of this cytostatic agent [39]. 
The MT levels have been found to be elevated in 
the epidermis after acute ultraviolet radiation 
exposure [40].
2.5.2 Metallothionein expression 
in inflammatory conditions
MT knockout mice appear relatively healthy, 
but they show an impaired response to stress 
[5]. MT expression is induced by a variety of 
pro- and anti-inflammatory mediators inclu-
ding glucocorticoids, reactive oxygen species, 
antioxidants, endotoxin, acute phase cytokines, 
furthermore, MT have a wide range of functions 
in cellular homeostasis and immunity [41]. 
Altered expression of MT has been shown in 
many inflammatory conditions. For example, an 
IHC study on renal biopsies from patients with 
lupus nephritis showed the depletion of MT-I 
and MT-II protein expression in the proximal 
tubular epithelial cells compared with healthy 
kidney specimens [42]. Moreover, a tubular MT 
score below the median value of the cohort pre-
dicted a poor renal outcome. Tissue infiltrating 
MT-positive cells could be shown in colonic 
biopsies from patients with inflammatory bo-
wel disease and acute infectious colitis [43]. In 
another study, the mucosal MT concentration 
in colonic tissue samples from patients with 
inflammatory bowel disease has been found to 
be lower compared with normal mucosa tissue 
samples suggesting an antioxidant imbalance in 
the intestinal mucosa of these patients [44,45]. 
In a dextran sulfate sodium-induced intestinal 
inflammation mouse model MT-positive cells 
were detected in the lamina propria and sub-
mucosal layer and were mainly co-localized in 
macrophages [46]. Nevertheless, the increase 
of colonic myeloperoxidase activity levels and 
pro-inflammatory cytokine production induced 
by dextran sulfate sodium was significantly 
higher in the MT-I/II knockout animals com-
pared with the wild-type mice suggesting that 
MT plays a protective role against colitis [46].
MT expression was analyzed in the central 
nervous system of mice with experimental auto-
immune encephalomyelitis [47]. MT-I/II seemed 
to be produced mainly by reactive astrocytes 
and activated macrophages. It was assumed that 
the elevation of MT expression level in tissue 
may act on the inflammatory microenviron-
ment suppressing pro-inflammatory cytokine 
production of macrophages, decreasing apopto-
tic cell death in neurons and oligodendrocytes, 
and enhancing tissue repair [47].
2.5.3 Metallothionein expression in cancer
MT expression in tissues has been studied 
most intensively in human cancers [48]. The 
results suggest that change in MT levels might 
play a role in the conversion of a potentially 
malignant lesion to a malignant carcinoma. 
For example, significantly higher MT-I/II and 
MT-III expression was noted in actinic keratosis 
and cutaneous squamous cell cancer, as compa-
red with normal skin epidermis, whereas very 
low levels of MT-III expression were found in 
basal cell cancer [22,29]. A significantly higher 
MT-I/II expression was also observed in oral 
squamous cell carcinoma tissues comparing 
with normal and oral leukoplakia epithelial 
tissues [49]. High MT expression was detected 
in pancreas adenocarcinoma tissues compared 
with pancreatic serous cystadenoma or heal-
thy pancreatic tissue samples [50]. Analysis of 
MT-I/II expression in prostate epithelial cells 
showed higher MT expression in tissues derived 
from benign prostatic hyperplasia than in those 
derived from prostate cancer [51]. Further-
more, IHC analysis of specimens from normal 
colorectal mucosa, adenomas, carcinomas and 
lymph node metastases revealed the down-re-
gulation of MT-I/II expression in association 
with colorectal cancer progression [52]. Janssen 
et al. confirmed that the MT concentrations 
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of colorectal adenomas, carcinomas and liver 
metastases are lower than that of corresponding 
normal mucosa, however, they have found that a 
relatively high MT content might be associated 
with the aggressiveness of colorectal cancers 
[53]. Meta-analysis of IHC studies led to the 
conclusion that significantly increased MT-I/
II expression can be detected in head and neck, 
and ovarian cancers, respectively, compared 
with healthy tissues, but significantly decreased 
MT expression can be observed in liver tumours 
compared with normal liver tissue [54]. It seems 
that the expression of MT is not universal to 
all human tumours, but may depend on the 
differentiation status and proliferative index 
of tumours, along with other tissue factors and 
gene mutations [48]. The various tumours may 
also differ in the intracellular localization of MT. 
For example, we observed nuclear MT-I/II stai-
ning in benign melanocytic nevi and intensive 
cytoplasmic and nuclear staining in malignant 
melanomas (Figure 2.) [9]. Cytoplasmic and 
nuclear MT-I/II expression was significantly 
higher in endometrial cancer cells compared 
with cells in benign hyperplasia of endome-
trium, however, the nuclear MT expression 
correlated better with histologic grade [55].
Changes in MT expression (up- or down-regu-
lation) may be associated with a more aggressive 
phenotype and therapeutic resistance, ultimate-
ly resulting in a worse prognosis [6,21]. Weinlich 
et al. have found that high MT levels in tumour 
cells are associated with reduced survival in 
patients with malignant melanoma [56]. We 
confirmed that high expression of MT-I/II in 
melanoma cells is significantly more frequent 
in primary cutaneous malignant melanoma 
with haematogenous metastases [9]. In bladder 
cancer patients a high MT expression in tumour 
tissues was linked to shorter tumour-specific 
survival and increased recurrence rates [57]. 
IHC analysis of specimens from renal cell car-
cinoma revealed that MT immunostaining is 
associated with significantly worse prognosis 
[58]. The absence of MT expression in ovari-
an cancer samples correlated with improved 
progression-free survival in patients treated 
with adjuvant platinum-based chemotherapy 
[59]. Nevertheless, the role of MT in metastasis 
formation remains to be confirmed, and ex-
perimental evidence for its oncogenic role is 
still lacking.
Figure 2: Expression of MT-I/II in primary 
cutaneous malignant melanoma cells (arrows). 
The keratinocytes (asterisks) of epidermal 
basal layer served as internal positive tissue 
controls. The IHC detection was based on 
an immunoperoxidase reaction using VIP 
chromogenic substrate. The slides were 
counterstained with methyl-green. Original 
magnification is x20.
 
3. Conclusions
Zn (II) is essential in fine-tuned orchestration 
of basic cell functions such as proliferation, gene 
expression and stress response. Besides metal 
detoxification, MT can release/bind Zn (II) with 
high affinity and regulates the availability of 
Zn (II) in various cell compartments thereby 
influencing the function of many transcription 
factors and enzymes [5]. It might explain why 
we can detect changes in the expression of MT 
in cancer, and calls for further investigations 
in this field. Moreover, the availability of zinc 
from MT is controlled by the local redox sta-
tus [4]. Alterations in reactive oxygen species 
homeostasis are thought to be involved in the 
pathogenesis of various diseases, including 
cancers [6]. IHC is suitable to demonstrate MT 
expression in its morphological and functional 
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context; therefore, it is an important element of 
the investigations. Assay standardization and 
the use of appropriate positive and negative 
tissue controls are very important to interpret 
the findings correctly.
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